Research
expert reaction to a retrospective cohort study looking at GLP-1 RA discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes
The Brief
- A retrospective cohort study in The Lancet Regional Health – Europe examines GLP-1 receptor agonist discontinuation in people with type 2 diabetes.
- The study looks at cardiovascular events and all-cause mortality associated with stopping these drugs.
- A Science Media Centre expert reaction to the study was published on 2026-11-10.
Why it matters
Clinicians and patients weigh whether to continue or stop GLP-1 receptor agonists, so an association between stopping and cardiovascular outcomes bears on that decision. Retrospective cohort designs show associations rather than proof of cause, so readers should check the study's details.
Who’s affected
- people with type 2 diabetes
- clinicians prescribing GLP-1 receptor agonists
Scientist responds to a retrospective cohort study published in The Lancet Regional Health – Europe* looking at GLP-1 RA discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes. Prof Naveed Sattar, Professor of Cardiometabolic…